ARA-290 Innate Repair Receptor Research

ARA-290 is a synthetic linear peptide corresponding to a short stretch of amino acids that form the aqueous-facing surface of helix B in erythropoietin (EPO), a region of the molecule not involved in binding the classical EPO receptor homodimer that drives erythrocyte production. It is also known by its International Nonproprietary Name, cibinetide, and is sometimes referred to in the literature as Helix B Surface Peptide (HBSP). The peptide was developed by Michael Brines, Anthony Cerami, and colleagues, building on earlier work characterizing EPO derivatives that retain tissue-protective activity without stimulating erythropoiesis.

The research premise is one of pharmacological separation: intact EPO has long been known to protect tissue from ischemic, traumatic, and inflammatory injury in addition to its blood-forming role, but clinical use of EPO for tissue protection is limited by the cardiovascular risks of elevated hematocrit. ARA-290 was engineered specifically to isolate the protective signaling from the erythropoietic signaling.

The foundational discovery underlying ARA-290 came from Brines and colleagues (2004), publishing in PNAS, who identified that EPO’s tissue-protective effects are mediated by a distinct receptor complex rather than the classical EPO receptor homodimer. The research demonstrated that the EPO receptor (EPOR) physically associates with the common beta receptor (betacR, also called CD131), the signal-transducing subunit shared by several cytokine receptors, to form a heterocomplex. Because betacR knockout mice show normal erythrocyte maturation, this heterocomplex, now referred to as the innate repair receptor (IRR), was established as unnecessary for erythropoiesis but required for EPO’s tissue-protective actions in the models tested.

Building directly on this discovery, Brines and colleagues (2008), also in PNAS, mapped the tissue-protective activity to the helix B region of EPO and then to the 11-amino-acid peptide that became ARA-290. The research reported that this short peptide was tissue-protective in models of ischemic stroke and renal ischemia-reperfusion injury, accelerated wound healing, and augmented cognitive function in rodents, while confirming it was not erythropoietic in either in vitro or in vivo testing.

The most developed clinical research program for ARA-290 concerns small fiber neuropathy (SFN) associated with sarcoidosis, an inflammatory disease that damages small and autonomic nerve fibers. The strongest evidence comes from Culver and colleagues (2017), publishing in Investigative Ophthalmology and Visual Science, who conducted a phase 2b, 28-day, randomized, placebo-controlled trial in 64 subjects. The trial used corneal confocal microscopy to measure corneal nerve fiber area (CNFA) as a surrogate marker of nerve repair.

The research reported a statistically significant placebo-corrected increase in CNFA of 697 μm2 in the 4 mg per day dosing group (P = 0.012), along with increased regenerating intraepidermal nerve fibers in that group. Changes in corneal nerve fiber area correlated with both nerve fiber regeneration markers and improved six-minute walk test distance. Pain improved across all dosing groups, with subjects reporting moderate to severe pain showing the largest reduction in the 4 mg group.

Beyond sarcoidosis, ARA-290 has been examined in type 2 diabetes with painful neuropathy. Brines and colleagues (2015), publishing in Molecular Medicine, conducted a phase 2 study in which subjects self-administered 4 mg of ARA-290 or placebo subcutaneously for 28 days. The research reported improvement in hemoglobin A1c and lipid profiles over the 56-day observation period, along with significant improvement in neuropathic symptoms measured by the PainDetect questionnaire. Subjects with reduced corneal nerve fiber density at baseline showed a significant increase in fiber density following treatment.

A related 2018 study by Brines and colleagues in Scientific Reports examined corneal nerve fiber size specifically, comparing patients with diabetic and sarcoidosis-associated small fiber neuropathy, including those who had received cibinetide. The research proposed that corneal nerve fiber area, in addition to standard corneal confocal microscopy variables like density and branch density, adds diagnostic sensitivity and is useful for quantifying treatment-related change in nerve morphology. Together, this body of work positions corneal confocal microscopy as a recurring, non-invasive outcome measure across the ARA-290 clinical research program.

ARA-290 has a more developed human clinical research record than many peptides discussed on this site, including a randomized, placebo-controlled phase 2b trial. That said, several limitations are worth stating plainly. The published literature is concentrated among a relatively small, overlapping group of investigators and institutions, principally Araim Pharmaceuticals and Warren Pharmaceuticals along with academic collaborators in Leiden, Manchester, and Cleveland. The 2008 PNAS paper mapping the peptide’s structure discloses that several authors were employees of Warren Pharmaceuticals, the company developing EPO analogs and tissue-protective compounds commercially at the time, a disclosed financial interest worth factoring into how the foundational findings are weighed.

All published trials to date are early-phase (phase 2 or 2b) with relatively small subject numbers, and no phase 3 trial data has been reported. Corneal nerve fiber measures function as surrogate endpoints, meaning they indicate biological activity but are not themselves direct measures of disease outcome. ARA-290 should be understood as a research peptide with a promising but still early and single-program-concentrated evidence base, not a validated intervention for any condition.

Preclinical and clinical literature has examined ARA-290 across several interconnected research contexts: